PLX Protalix BioTherapeutics, Inc. Common Stock
XASE
2.78
Delayed
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
- 52-Week Range
- $1.60 – $3.19
- YTD
- +59.77%
- Straddle Price
- $0.95
- P/C Vol Ratio
- 1.00
- Market Cap
- $0.2B
- Open
- $2.70
- Day Range
- $2.69 – $2.79
- Volume
- 1,198,885
- Prev Close
- $2.70
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 5.27% |
| Beta vs SPY | 0.86 |
| Cost of Equity (CAPM) | 9.59% (VRP-adj) |
| WACC | 9.54% |
| Volatility Risk Premium | +108.7pp (IV − HV30) |
| Effective Tax Rate | 19.3% |
| Rev. Growth (YoY, DCF input) | +11.5% |
| DCF Horizon | 10 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.10 (applied to P/E, EV/EBITDA, P/S) |
| Free Cash Flow (TTM) | $0.0B |
| Return on Equity (TTM) | 26.5% |
| Book / Price | 32.9% — banking bias active (P/B is primary) |
| Gross Margin (TTM) | 69.2% |
| FCF Margin (TTM) | 9.5% |
| Debt / Equity | 0.00 |
| Quality Score | 3/6 — normal (10y DCF) |
| Market-Implied Growth | +11.7% (reverse-DCF on current price) |
| SMA 50 | $2.57 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $2.72 |
| Bollinger Width / SMA20 | 253.1% (drives anchor stability) |
| Net Debt | $-0.0B |
| Market Cap | $0B |
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | $2.67 | 16% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | $5.81 | 14% | median 23.0× · 4 peers |
| Peer EV/EBITDA | $5.53 | 14% | median 15.3× · 4 peers |
| Peer P/B | $3.43 | 3% | median 3.9× · 4 peers |
| Peer P/S | $2.12 | 9% | median 1.9× · 4 peers |
| Market Anchor (SMA50) | $2.57 | 44% | stability 71% (BB-width) |
| Options Expected (B-L 30d) | n/a | 0% |

- Industry (SIC)
- BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) (2836)
- Exchange
- XASE
- Market Cap
- $0.2B
- Employees
- 226
- List Date
- 1996-01-02
- CIK
- 0001006281
- Next Earnings
- 2026-11-12 (Pre-Market)
- EPS Forecast
- ($0.02) (2 est.)
- Headquarters
- Hackensack, NJ
- Homepage
- https://www.protalix.com
Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | 22.35% | -7.46% | 13.87% | -20.33% | 23.35% | 34.48% | 11.04% |
| Feb | 11.11% | -4.66% | 19.75% | 10.88% | -3.72% | 10.77% | 7.36% |
| Mar | -8.42% | 26.19% | 6.06% | -22.22% | 10.82% | -28.38% | -2.66% |
| Apr | -25.39% | 10.48% | 25.79% | -8.80% | 20.87% | -1.83% | 3.52% |
| May | -4.10% | 4.42% | -27.93% | -6.61% | -48.33% | -0.47% | -13.84% |
| Jun | -35.91% | -9.17% | -6.54% | 1.74% | -6.33% | 13.11% | -7.18% |
| Jul | -19.25% | -2.30% | -13.04% | -7.69% | -1.35% | 2.60% | -6.84% |
| Aug | 3.80% | 5.21% | 15.95% | -10.92% | 6.90% | 10.78% | 5.29% |
| Sep | -16.35% | -4.02% | -16.16% | -4.67% | 35.37% | 6.56% | 0.12% |
| Oct | -9.60% | -1.90% | 7.05% | 11.43% | 0.42% | 3.73%* | 1.86% |
| Nov | -15.91% | 5.77% | -6.79% | 37.60% | -25.52% | -- | -0.97% |
| Dec | -6.40% | 24.55% | 21.92% | 12.57% | 5.88% | -- | 11.70% |
| Total | -71.52% | 48.74% | 26.02% | -19.44% | -12.96% | 48.13% | 3.16% |
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
Momentum Oscillators
Volume & Volatility
Data Summary
LLM Stock Analysis Report
Executive Summary
Overall Assessment: BEARISH (Confidence Level: 6/10)
Key Drivers:
- High volatility, as indicated by beta (1.30) and stock volatility (0.65)
- Recent news headlines suggesting positive sentiment, but not strong enough to overcome bearish technical signals
- Earnings data unavailable
Primary Risks:
- Weak trend regime (ADX: 23.62), indicating a lack of directional momentum
- Overbought RSI reading (49.11), suggesting potential for price reversal
2-3 sentence Investment Thesis: PLX is likely to experience a pullback due to its overbought condition and weak trend, despite positive recent news headlines. As volatility remains high, investors should be cautious and consider hedging strategies.
Recent News Sentiment Impact: The positive sentiment from the recent news headlines (Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Approval of Additional Dosing Regimen) may have contributed to the short-term bullish momentum, but it is not enough to overcome the bearish technical signals.
Technical Analysis
Trend Direction: Short-term (1-4 weeks): BEARISH, Medium-term (1-3 months): NEUTRAL, Long-term (3-12 months): NEUTRAL
Support/Resistance Levels:
- Lower band: $2.20
- Middle band: $2.38
- Upper band: $2.55
Momentum Signals: RSI interpretation: OVERBOUGHT (49.11) MACD signal: BULLISH (0.01 / Signal: -0.02 / Histogram: 0.03), but MACD is near the zero line, indicating a potential reversal Bollinger Bands position: SQUEEZE
Volume Analysis: Volume trends suggest institutional interest waning.
News & Sentiment Analysis
Recent Headlines Summary: The news headlines highlight positive developments for PLX, including regulatory approvals and company acquisitions.
Sentiment Assessment: Aggregate sentiment is POSITIVE (60%), but it may not be strong enough to overcome the bearish technical signals.
Catalyst Identification: Upcoming earnings data availability could provide a catalyst for price movement.
Market Narrative: The recent news headlines contradict the bearish technical signals, indicating potential for price reversal or consolidation.
Risk & Volatility Assessment
Beta Interpretation: High risk (beta: 1.30), as PLX is more volatile than the market.
Volatility Regime: High volatility (0.65).
Options Market Signals: IV Rank: 50.9% (Medium - shows if volatility is historically high/low) Current IV: 147.8% Expected Move: $0.42 (31 DTE), 7-DTE: $1.30 Volume Flow: 1 calls vs 0 puts Open Interest: 7 calls vs 0 puts Put/Call Volume Ratio: 0.00 (Bullish sentiment) Put/Call OI Ratio: 0.00
Downside Protection: Support levels are at $2.20 and $2.38.
Market Context & Positioning
Sector Performance: PLX is relatively strong compared to its sector, but it is not a leader in terms of performance.
Institutional Activity: Volume patterns suggest institutional interest waning.
Correlation Analysis: PLX has a moderate correlation with the market (R-squared: 0.26).
Relative Valuation: PLX is trading within its historical range.
Key Levels & Action Items
Critical Price Levels:
- Lower band: $2.20
- Middle band: $2.38
- Upper band: $2.55
Breakout/Breakdown Levels:
- Support: $2.20, $2.29 (SMA 50)
- Resistance: $2.37 (EMA 12), $2.55 (Upper band)
Time-Sensitive Catalysts: Earnings data availability could provide a catalyst for price movement.
Risk Management: Consider hedging strategies due to high volatility and bearish technical signals.
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2021-05-14 | Pre-Market | 17.42% | 4.53% | 0.26x | Within |
| 2021-08-16 | Pre-Market | 32.84% | 1.49% | 0.05x | Within |
| 2021-11-15 | Pre-Market | 94.74% | 0.88% | 0.01x | Within |
| 2022-03-31 | Pre-Market | 16.19% | 0.95% | 0.06x | Within |
| 2022-05-16 | Pre-Market | 14.15% | 0.94% | 0.07x | Within |
| 2022-08-15 | Pre-Market | 18.78% | 1.22% | 0.06x | Within |
| 2023-02-27 | Pre-Market | 106.04% | 2.75% | 0.03x | Within |
| 2023-05-04 | Pre-Market | 34.29% | 6.67% | 0.19x | Within |
| 2023-08-07 | Pre-Market | 25.90% | 14.46% | 0.56x | Within |
| 2023-11-06 | Pre-Market | 25.95% | 18.38% | 0.71x | Within |
| 2024-05-10 | Pre-Market | 22.40% | 12.00% | 0.54x | Within |
| 2024-08-14 | After-Close | 153.23% | 2.15% | 0.01x | Within |
| 2024-11-14 | Pre-Market | 18.15% | 13.71% | 0.76x | Within |
| 2025-03-17 | Pre-Market | 24.55% | 9.37% | 0.38x | Within |
| 2025-05-09 | Pre-Market | 16.44% | 40.48% | 2.46x | Exceeded |
| 2025-08-14 | Pre-Market | 139.75% | 5.59% | 0.04x | Within |
| 2025-11-13 | Pre-Market | 29.21% | 9.81% | 0.34x | Within |
| 2026-03-18 | Pre-Market | 17.92% | 20.79% | 1.16x | Exceeded |
| 2026-05-13 | Pre-Market | 14.40% | 1.05% | 0.07x | Within |
| 2026-08-12 | After-Close | 14.31% | 9.92% | 0.69x | Within |
Earnings calendar: this week’s reports with expected vs actual moves →
PLX Options Activity & IV Rank
Volatility Metrics
Options Flow
ATM Options Pricing
Chain Summary
Each spread is ranked by a composite score built in three stages. Full documentation →
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Estimated net dealer gamma is at the 99th percentile of this name's own daily history, near the high end of its range. This describes current positioning; it is not a forecast or a trading signal.
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Enter a ticker to render the implied volatility surface.
Enter a ticker to render the implied volatility smile.
Risk Metrics
Analysis Details
Data Points: 251
Period: 252 trading days
Above average volatility - stock moves with market amplification
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Renaissance Technologies Hedge fund Jim Simons | $2.6M | #1830 of 3138 | -10.5% | 13F | |
| Citadel Hedge fund Ken Griffin | $779K | #3990 of 6285 | new | 13F | |
| Millennium Management Hedge fund Izzy Englander | $400K | #3255 of 3717 | new | 13F | |
| Point72 Hedge fund Steve Cohen | $60K | #1869 of 1946 | new | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
PLX Institutional Ownership (13F)
Latest filings — 2026-09-30Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Susquehanna International Group, LLP Custodian | $456.91K | 61.13% | 2026-06-30 |
| 2 | GROUP ONE TRADING LLC Custodian | $174.05K | 23.29% | 2026-06-30 |
| 3 | Jane Street Group, LLC Custodian | $91.57K | 12.25% | 2026-06-30 |
| 4 | Simplex Trading, LLC Custodian | $24.93K | 3.34% | 2026-06-30 |
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Susquehanna International Group, LLP Custodian | $166.83K | 31.50% | 2026-06-30 |
| 2 | Citadel Advisors LLC Custodian | $105.32K | 19.89% | 2026-06-30 |
| 3 | Jane Street Group, LLC Custodian | $85.98K | 16.23% | 2026-06-30 |
| 4 | Wolverine Trading, LLC Custodian | $70.85K | 13.38% | 2025-09-30 |
| 5 | Simplex Trading, LLC Custodian | $64.77K | 12.23% | 2026-06-30 |
| 6 | GROUP ONE TRADING LLC Custodian | $35.88K | 6.78% | 2026-06-30 |
PLX Insider Trading (Form 4)
Latest: 2026-09-09| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-09-09 | Aharon Schwartz | Director | Grant (A) | +25,500 opt | — | EDGAR | |
| 2026-09-04 | Zvi Shmuel Ben | Director | Grant (A) | +25,500 RSU | — | EDGAR | |
| 2026-09-04 | Pol F Boudes | Director | Grant (A) | +25,500 opt | — | EDGAR | |
| 2026-09-04 | Dror Bashan | PRESIDENT AND CEO | Grant (A) | +480,000 RSU | — | EDGAR | |
| 2026-09-04 | Eliot Forster | Director | Grant (A) | +25,500 RSU | — | EDGAR | |
| 2026-09-04 | Yaron Naos | Sr. VP & COO | Grant (A) | +168,000 opt | — | EDGAR | |
| 2026-09-04 | Christian Elze | Director | Grant (A) | +25,500 opt | — | EDGAR | |
| 2026-09-04 | Amos Bar-Shalev | Director | Grant (A) | +25,500 opt | — | EDGAR | |
| 2026-09-04 | Gwen A Melincoff | Director | Grant (A) | +25,500 RSU | — | EDGAR | |
| 2025-12-23 | Dror Bashan | PRESIDENT AND CEO | Buy (P) | +56,000 | $1.81 | $101.4K | EDGAR |
| 2025-11-19 | Amos Bar-Shalev | Director | Sell (S) | −168 | $1.87 | -$314 | EDGAR |
| 2025-09-04 | Gwen A Melincoff | Director | Award (A) | +7,500 | — | EDGAR | |
| 2025-09-04 | Christian Elze | Director | Award (A) | +7,500 | — | EDGAR | |
| 2025-09-04 | Zvi Shmuel Ben | Director | Award (A) | +7,500 | — | EDGAR | |
| 2025-09-04 | Aharon Schwartz | Director | Award (A) | +7,500 | — | EDGAR |
PLX Insider Holdings
10 insiders · @ $2.78| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Dror Bashan | PRESIDENT AND CEO | 2,532,934 | $7.04M | $293.8K | 12 | 2026-09-04 |
| 2 | Eyal Rubin | Sr. VP and CFO | 660,909 | $1.84M | $0 | 8 | 2024-11-05 |
| 3 | Aharon Schwartz | Director | 310,500 | $863.2K | $517.0K | 8 | 2026-09-09 |
| 4 | Yaron Naos | Sr. VP & COO | 232,929 | $647.5K | $0 | 7 | 2026-09-04 |
| 5 | Pol F Boudes | Director | 7,540 | $21.0K | $0 | 5 | 2026-09-04 |
| 6 | Amos Bar-Shalev | Director | 7,500 | $20.9K | $13.9K | 7 | 2026-09-04 |
| 7 | Gwen A Melincoff | Director | 7,500 | $20.9K | $0 | 5 | 2026-09-04 |
| 8 | Eliot Forster | Director | 7,500 | $20.9K | $0 | 3 | 2026-09-04 |
| 9 | Zvi Shmuel Ben | Director | 7,500 | $20.9K | $0 | 5 | 2026-09-04 |
| 10 | Christian Elze | Director | 7,500 | $20.9K | $0 | 2 | 2026-09-04 |
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | VXUS Vanguard Total International Stock ETF | Vanguard | 0.00% | $20.3M | — | 2026-08-31 |
| 2 | VEA Vanguard FTSE Developed Markets ETF | Vanguard | 0.00% | $13.3M | — | 2026-08-31 |
| 3 | IEFA iShares Core MSCI EAFE ETF | iShares (BlackRock) | 0.01% | $10.7M | $189.5B | 2026-10-08 |
| 4 | IWM iShares Russell 2000 ETF | iShares (BlackRock) | 0.01% | $5.3M | $78.7B | 2026-10-08 |
| 5 | VSS Vanguard FTSE All-World EX-US Small-Cap Index Fund | Vanguard | 0.03% | $5.3M | — | 2026-08-31 |
| 6 | SCZ iShares MSCI EAFE Small-Cap ETF | iShares (BlackRock) | 0.04% | $4.8M | $12.9B | 2026-10-08 |
| 7 | VGK Vanguard FTSE Europe ETF | Vanguard | 0.01% | $3.2M | — | 2026-08-31 |
| 8 | IDEV iShares Core MSCI International Developed Markets ETF | iShares (BlackRock) | 0.01% | $2.1M | $33.1B | 2026-10-08 |
| 9 | IWO iShares Russell 2000 Growth ETF | iShares (BlackRock) | 0.01% | $2.0M | $13.9B | 2026-10-08 |
| 10 | IXUS iShares Core MSCI Total International Stock ETF | iShares (BlackRock) | 0.00% | $1.8M | $58.6B | 2026-10-08 |
| 11 | VTWO Vanguard Russell 2000 ETF | Vanguard | 0.01% | $1.1M | — | 2026-08-31 |
| 12 | VT Vanguard Total World Stock ETF | Vanguard | 0.00% | $1.1M | — | 2026-08-31 |
| 13 | IWC iShares Micro-Cap ETF | iShares (BlackRock) | 0.05% | $684,725 | $1.3B | 2026-10-08 |
| 14 | VTWG Vanguard Russell 2000 Growth ETF | Vanguard | 0.01% | $207,576 | — | 2026-08-31 |
| 15 | VSGX Vanguard ESG International Stock ETF | Vanguard | 0.00% | $201,020 | — | 2026-06-30 |
| 16 | EES WisdomTree U.S. SmallCap Fund | Nport | 0.03% | $182,316 | — | 2027-03-31 |
| 17 | IEUS iShares MSCI Europe Small-Cap ETF | iShares (BlackRock) | 0.09% | $141,551 | $163.2M | 2026-10-08 |
| 18 | RSSL Global X Russell 2000 ETF | Global X | 0.01% | $99,235 | — | 2026-10-09 |
| 19 | SPEU State Street® SPDR® Portfolio Europe ETF | SPDR (State Street) | 0.01% | $56,790 | $683.4M | 2026-10-08 |
| 20 | DFSU Dimensional US Sustainability Core 1 ETF | Nport | 0.00% | $16,579 | — | 2026-10-31 |
| 21 | VTHR Vanguard Russell 3000 ETF | Vanguard | 0.00% | $14,199 | — | 2026-08-31 |
| 22 | ITWO ProShares Russell 2000 High Income ETF | ProShares | 0.00% | $12,888 | — | 2026-10-09 |
| 23 | URTY ProShares UltraPro Russell2000 | ProShares | 0.00% | $9,071 | — | 2026-10-09 |
| 24 | UWM ProShares Ultra Russell2000 | ProShares | 0.00% | $5,352 | — | 2026-10-09 |
| 25 | IVSS Applied Finance IVS US SMID ETF | Nport | 0.03% | $4,166 | — | 2026-12-31 |
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Quarterly figures (12 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q2 '26 | 2026-06-30 | $19.90M | $3.78M | $0.05 | $-10.40M |
| Q1 '26 | 2026-03-31 | $33.75M | $18.32M | $0.22 | $22.02M |
| Q4 '25 | 2025-12-31 | $9.12M | $-5.50M | $-0.07 | $2.03M |
| Q3 '25 | 2025-09-30 | $17.85M | $2.35M | $0.03 | $-3.73M |
| Q2 '25 | 2025-06-30 | $15.66M | $164.00K | $0.00 | $-5.23M |
| Q1 '25 | 2025-03-31 | $10.11M | $-3.62M | $-0.05 | $-5.06M |
| Q4 '24 | 2024-12-31 | $18.22M | $6.49M | $0.09 | $3.99M |
| Q3 '24 | 2024-09-30 | $17.96M | $3.24M | $0.03 | $4.11M |
| Q2 '24 | 2024-06-30 | $13.47M | $-2.20M | $-0.03 | $-3.61M |
| Q1 '24 | 2024-03-31 | $3.75M | $-4.59M | $-0.06 | $4.19M |
| Q4 '23 | 2023-12-31 | $10.49M | $-6.04M | $-0.07 | $3.60M |
| Q3 '23 | 2023-09-30 | $10.35M | $-1.85M | $-0.04 | $-6.89M |
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.